Kinnate Biopharma Stock (NASDAQ:KNTE)


ForecastOwnershipFinancialsChart

Previous Close

$2.66

52W Range

$1.04 - $7.18

50D Avg

$2.49

200D Avg

$2.25

Market Cap

$124.99M

Avg Vol (3M)

$367.16K

Beta

1.34

Div Yield

-

KNTE Company Profile


Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

84

IPO Date

Dec 03, 2020

Website

KNTE Performance


KNTE Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-119.01M$-118.52M$-90.11M
Net Income$-112.65M$-114.02M$-89.42M
EBITDA$-118.21M$-117.92M$-89.99M
Basic EPS$-2.42$-2.59$-2.05
Diluted EPS$-2.42$-2.59$-2.05

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
SLRNAcelyrin, Inc.
LRMRLarimar Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
STOKStoke Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
ERASErasca, Inc.
GBIOGeneration Bio Co.
SRZNSurrozen, Inc.
KRONKronos Bio, Inc.
PASGPassage Bio, Inc.
BOLTBolt Biotherapeutics, Inc.
KROSKeros Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
WINTWindtree Therapeutics, Inc.
KZRKezar Life Sciences, Inc.
FIXXQ32 Bio Inc.
PALIPalisade Bio, Inc.